Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to -$7.0 million.

  • Dna X's Cash from Operations fell 158681.06% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$26.0 million, marking a year-over-year decrease of 50145.56%. This contributed to the annual value of -$8.5 million for FY2024, which is 10942.74% down from last year.
  • Dna X's Cash from Operations amounted to -$7.0 million in Q3 2025, which was down 158681.06% from -$4.9 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Cash from Operations ranged from a high of $820000.0 in Q2 2023 and a low of -$17.6 million during Q4 2021
  • Moreover, its 5-year median value for Cash from Operations was -$4.2 million (2023), whereas its average is -$4.5 million.
  • In the last 5 years, Dna X's Cash from Operations surged by 11090.21% in 2022 and then plummeted by 561785.71% in 2025.
  • Quarter analysis of 5 years shows Dna X's Cash from Operations stood at -$17.6 million in 2021, then soared by 87.34% to -$2.2 million in 2022, then surged by 84.21% to -$351000.0 in 2023, then plummeted by 1184.62% to -$4.5 million in 2024, then crashed by 56.0% to -$7.0 million in 2025.
  • Its Cash from Operations stands at -$7.0 million for Q3 2025, versus -$4.9 million for Q2 2025 and -$9.6 million for Q1 2025.